Paclitaxel as first- or second-line treatment for HIV-negative Kaposi’s sarcoma: a retrospective study of 58 patients

Paclitaxel as first- or second-line treatment for HIV-negative Kaposi’s sarcoma: a retrospective study of 58 patients

Background: Paclitaxel has recently been approved for AIDS-related Kaposi’s sarcoma (KS) and there is much interest also in HIV-negative KS. Objective: To assess the safety and effectiveness of intravenous paclitaxel in the treatment of non-HIV-associated KS. Method: A retrospective database analysi...

Full description

Bibliographic Details
Main Authors: Athanasia Tourlaki, Francesca Germiniasi, Luisa Carlotta Rossi, Stefano Veraldi, Lucia Brambilla
Format: Article
Language:English
Published: Taylor & Francis Group 2020-02-01
Series:Journal of Dermatological Treatment
Subjects:
kaposi’s sarcoma
intravenous paclitaxel
taxanes
treatment
chemotherapy
Online Access:http://dx.doi.org/10.1080/09546634.2019.1590520

Internet

http://dx.doi.org/10.1080/09546634.2019.1590520

Similar Items